Abbott Laboratories CEO Sells Over $46M in Stock

On August 25, 2026, Robert B. Ford, the Chairman and CEO of Abbott Laboratories, executed a series of transactions involving the company's common stock.

Transaction Breakdown:

• Option Exercise (Acquisition): Ford exercised options to acquire a total of 398,832 common shares. These acquisitions were made at predetermined exercise prices of $44.40 and $59.94 per share.
• Open Market Sale (Disposition): Concurrently, Ford sold 398,832 common shares on the open market. The sales occurred at weighted average prices of approximately $115.57 and $116.19, for a total sale value of approximately $46.2 million.

Analysis: The transactions represent a classic 'exercise-and-sell' strategy, which is a common way for executives to monetize vested stock options. The number of shares acquired through the option exercise is identical to the number of shares sold, indicating that the primary purpose was likely liquidity and financial planning rather than a change in the executive's long-term view of the company. As a result of these transactions, Ford's direct share ownership in Abbott Laboratories remained unchanged at 306,461 shares. He also indirectly holds 216,203 shares via a family trust.